Blood thinner to carry gene test info, FDA says

WASHINGTON (Reuters) - Prescribing instructions for the generic blood thinner warfarin will carry new information advising doctors to consider adjusting the dose for people with certain genes, U.S. health officials said on Thursday.

Patients with specific genetic variations may need a lower dose of warfarin to reduce the risk of dangerous bleeding, said Larry Lesko, director of clinical pharmacology in the Food and Drug Administration's Center for Drug Evaluation and Research.